Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

Inexpensive combo-chemotherapy found to be better tolerated than BCG for common bladder cancer

An on-going, worldwide shortage of bacillus Calmette-Guérin (BCG) means that many patients with a common and serious type of bladder cancer have limited access to this effective standard of care treatment.

28 Feb 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

A novel prostate cancer treatment-;225Ac-PSMA-617 radioligand therapy-;has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.

9 Mar 2022

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

A new drug, administered in combination with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer, according to a trial published in The New England Journal of Medicine.

23 Feb 2022

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases.

18 Feb 2022

Regular blood tests can identify prostate cancer patients who are resistant to treatment

Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.

11 Nov 2021

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

Prostate cancer is the most common type of cancer among men in the United States aside from skin cancer, according to the Centers for Disease Control and Prevention.

8 Sep 2021

New drug shows promise against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

8 Jun 2021

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

A new drug reduced tumor size in patients who have lung cancer with a specific, disease-causing change in the gene KRAS, a study found.

7 Jun 2021

Study examines impact of chemotherapy on mechanical properties of prostate cancer cells

Malignant tumor cells undergo mechanical deformation more easily than normal cells, allowing them to migrate throughout the body.

28 May 2021

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

One in six men being treated for advanced prostate cancer experiences a reduced sense of smell and taste, a symptom that could cause increased anxiety among patients because it is also a side effect of COVID-19, according to Tulane researchers.

16 Mar 2021

Scientists test the effect of natural product isolated from sea sponge on cancer cells

Scientists from Far Eastern Federal University together with Russian and German colleagues, continue studying antitumor compounds synthesized based on bioactive molecules isolated from a sea sponge.

1 Mar 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Docetaxel News and Research

Further Reading

Inexpensive combo-chemotherapy found to be better tolerated than BCG for common bladder cancer

Rising Medicare costs linked to increased use of new prostate cancer therapies

Combination of three technologies makes potential treatment effective against aggressive brain tumor

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Regular blood tests can identify prostate cancer patients who are resistant to treatment

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

New drug shows promise against lung cancer caused by genetic mutation

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

Study examines impact of chemotherapy on mechanical properties of prostate cancer cells

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

Scientists test the effect of natural product isolated from sea sponge on cancer cells

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Scientists develop a lead compound to fight chemotherapy-resistant prostate cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI may help predict tumor sensitivity to systemic cancer therapies

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News